Sequana Medical NV
We are a commercial stage medical device company developing the alfapump® platform for the treatment of fluid overload in liver disease, malignant ascites and heart failure where diuretics are no longer effective. The alfapump®, is a fully implantable, programmable, wirelessly-charged, battery-powered system that is CE-marked for the treatment of refractory ascites due to liver cirrhosis and malignant ascites. Over 900 alfapump® systems have been implanted. The alfapump® has been endorsed by key independent third parties in Europe and has received Breakthrough Device status from the US FDA. We have leveraged our alfapump® technology experience and are developing alfapump DSR®, a novel and proprietary approach to the treatment of fluid overload in patients suffering from heart failure.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Medical Equipment
- Market Focus:
- Globally (various continents)
Our History
The concept of the alfapump® dates back to 2000 when a physician was searching for a better way to manage his ascites patients.
The first prototypes were built in 2005 and the founders demonstrated the technical feasibility of the approach. The first patients were implanted with a device in 2008 and in 2011 we received the CE-mark for removal of refractory ascites due to liver cirrhosis following completion of the PIONEER clinical study. The alfapump® was commercially launched at the EASL meeting in 2012 and in the same year the CE-mark was received for removal of malignant ascites.
Since then we have continued to invest in the clinical, technical and commercial development of the alfapump®. This includes the completion of the MOSAIC IDE feasibility study in North America in patients with recurrent and refractory liver ascites and the publication of the results of the European randomised controlled trial and the initial results of the Post-Marketing Surveillance Registry in patients with refractory liver ascites.
Following these studies, the alfapump® has been endorsed by key independent third parties in Europe and has been included in the EASL (European Association for the Study of the Liver) clinical practice guidelines for decompensated cirrhosis, the German treatment guidelines (DGVS) for complications of liver cirrhosis and the U.K. NICE interventional procedure guidance for treatment of refractory ascites caused by cirrhosis. In January 2019, the U.S. FDA granted the alfapump® Breakthrough Device designation for the treatment of recurrent or refractory liver ascites. The North American pivotal POSEIDON study to support marketing approval and reimbursement of the alfapump® in the U.S. and Canada is currently ongoing.
In 2017, we established DSR® (Direct Sodium Removal), a new breakthrough therapy in development for the treatment of fluid overload in patients suffering from heart failure, in collaboration with Dr. Jeffrey Testani, Associate Professor at Yale University. Pre-clinical and clinical proof-of-concept of DSR® was achieved and data from these studies have been published in the high impact clinical journal Circulation, indicating the potential of this therapeutic approach. RED DESERT was the first alfapump DSR® study in diuretic-resistant heart failure patients, combining DSR® therapy with our proven alfapump® platform, and demonstrated that repeated DSR therapy is able to both manage the fluid and sodium balance of these patients as well as restore their diuretic response and improve their cardio-renal status. The SAHARA DESERT study of alfapump® DSR in decompensated heart failure patients is ongoing.